Skip to main content

Table 1 Major inclusion and exclusion criteria

From: Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer

Major inclusion criteria

Major exclusion criteria

Female 18–70 years old

History of systemic anticancer therapy for invasive breast cancer, chemotherapy, or radiation therapy

HER2/neu positive or negative, histologically proven, lymph node-positive or high-risk lymph node-negative breast cancer

Cardiac disease or poorly controlled hypertension

Definitive breast surgery within 28 to 60 days consisting of mastectomy; breast conserving surgery with axillary lymph node dissection or sentinel lymph node biopsy for operable breast cancer (T1-3, N0-1, M0)

Other serious medical issues

Normal cardiac, hematologic, and liver function

Minor surgical procedure within 7 days or major surgical procedure within 28 days prior to day 1 of study treatment or any anticipated surgical procedure during the chemotherapy portion of the study